Tang Capital Management
Latest statistics and disclosures from Tang Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are AUPH, CELC, MIRM, GLPG, SPY, and represent 32.41% of Tang Capital Management's stock portfolio.
- Added to shares of these 10 stocks: SPY (+$90M), CORT (+$54M), CAPR (+$52M), INSM (+$33M), CMPS (+$22M), ANIP (+$17M), AUPH (+$13M), JANX (+$7.0M), CBIO (+$5.3M), AGIO.
- Started 4 new stock positions in LXRX, JANX, CMPS, AGIO.
- Reduced shares in these 10 stocks: Avidity Biosciences Ord (-$65M), , MRNA (-$30M), TVTX (-$27M), VTYX (-$25M), NVDA (-$24M), , GSK (-$15M), PCVX (-$13M), ERAS (-$11M).
- Sold out of its positions in ACAD, ACET, ARE, Avidity Biosciences Ord, BCRX, BMY, FLNA, DVAX, META, GSK.
- Tang Capital Management was a net seller of stock by $-83M.
- Tang Capital Management has $2.0B in assets under management (AUM), dropping by -2.74%.
- Central Index Key (CIK): 0001232621
Tip: Access up to 7 years of quarterly data
Positions held by Tang Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Tang Capital Management
Tang Capital Management holds 51 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Aurinia Pharmaceuticals (AUPH) | 9.2 | $181M | +7% | 12M | 14.82 |
|
| Celcuity (CELC) | 6.1 | $120M | 1.1M | 114.14 |
|
|
| Mirum Pharmaceuticals (MIRM) | 5.8 | $114M | 1.2M | 92.38 |
|
|
| Galapagos Nv Spon Adr (GLPG) | 5.8 | $114M | -3% | 3.8M | 30.00 |
|
| State Str Spdr S&p 500 Etf T Tr Unit (SPY) | 5.5 | $109M | +460% | 168k | 650.34 |
|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 5.5 | $109M | 2.3M | 48.15 |
|
|
| Capricor Therapeutics Com New (CAPR) | 5.2 | $103M | +99% | 3.4M | 30.40 |
|
| Ptc Therapeutics I (PTCT) | 5.2 | $102M | 1.5M | 68.13 |
|
|
| Spyre Therapeutics Com New (SYRE) | 4.8 | $95M | 1.9M | 50.44 |
|
|
| Kalvista Pharmaceuticals (KALV) | 4.7 | $92M | 4.6M | 20.13 |
|
|
| Compass Therapeutics (CMPX) | 4.5 | $89M | 17M | 5.29 |
|
|
| Tarsus Pharmaceuticals (TARS) | 4.2 | $83M | 1.2M | 70.15 |
|
|
| Immunocore Hldgs Ads (IMCR) | 4.1 | $80M | 2.6M | 30.15 |
|
|
| Anaptysbio Inc Common (ANAB) | 3.7 | $74M | 1.3M | 55.46 |
|
|
| Corcept Therapeutics Incorporated (CORT) | 3.1 | $61M | +856% | 1.5M | 40.31 |
|
| Biosante Pharmaceuticals (ANIP) | 2.8 | $54M | +46% | 708k | 76.90 |
|
| Insmed Com Par $.01 (INSM) | 2.2 | $43M | +333% | 260k | 163.52 |
|
| Biontech Se Sponsored Ads (BNTX) | 2.1 | $42M | 470k | 88.88 |
|
|
| Miragen Therapeutics (VRDN) | 1.8 | $35M | 1.8M | 19.56 |
|
|
| Atea Pharmaceuticals (AVIR) | 1.3 | $26M | 4.8M | 5.38 |
|
|
| Precigen (PGEN) | 1.3 | $25M | +14% | 6.4M | 3.87 |
|
| Dianthus Therapeutics (DNTH) | 1.1 | $22M | 265k | 83.92 |
|
|
| Compass Pathways Sponsored Ads (CMPS) | 1.1 | $22M | NEW | 4.0M | 5.53 |
|
| Crescent Biopharma (CBIO) | 1.1 | $21M | +32% | 1.2M | 18.37 |
|
| Stoke Therapeutics (STOK) | 0.8 | $16M | 500k | 32.56 |
|
|
| Viking Therapeutics (VKTX) | 0.8 | $16M | 500k | 32.54 |
|
|
| Ideaya Biosciences (IDYA) | 0.8 | $15M | 450k | 33.32 |
|
|
| Nuvation Bio Com Cl A (NUVB) | 0.7 | $14M | -18% | 3.1M | 4.29 |
|
| Pliant Therapeutics (PLRX) | 0.4 | $7.7M | 6.1M | 1.26 |
|
|
| Journey Med Corp (DERM) | 0.4 | $7.6M | -13% | 1.6M | 4.69 |
|
| Janux Therapeutics (JANX) | 0.4 | $7.0M | NEW | 500k | 13.90 |
|
| Biogen Idec (BIIB) | 0.3 | $6.4M | 35k | 183.33 |
|
|
| Urogen Pharma (URGN) | 0.3 | $6.3M | 350k | 17.98 |
|
|
| Arvinas Ord (ARVN) | 0.3 | $5.7M | -5% | 539k | 10.60 |
|
| Pmv Pharmaceuticals (PMVP) | 0.3 | $5.3M | -14% | 4.2M | 1.24 |
|
| Moderna (MRNA) | 0.3 | $5.1M | -85% | 100k | 50.80 |
|
| Heron Therapeutics (HRTX) | 0.3 | $5.0M | 6.3M | 0.80 |
|
|
| Kezar Life Sciences Com New (KZR) | 0.3 | $4.9M | 664k | 7.42 |
|
|
| Wave Life Sciences SHS (WVE) | 0.2 | $4.4M | 600k | 7.25 |
|
|
| Lenz Therapeutics (LENZ) | 0.2 | $4.1M | -47% | 451k | 9.15 |
|
| Agios Pharmaceuticals (AGIO) | 0.2 | $3.4M | NEW | 100k | 33.83 |
|
| Erasca (ERAS) | 0.2 | $3.2M | -77% | 200k | 16.18 |
|
| Coherus Biosciences (CHRS) | 0.2 | $3.2M | -30% | 1.9M | 1.69 |
|
| Nkarta (NKTX) | 0.2 | $3.1M | 1.5M | 2.11 |
|
|
| Altimmune Com New (ALT) | 0.1 | $2.1M | -68% | 666k | 3.08 |
|
| Evolus (EOLS) | 0.1 | $2.0M | -61% | 483k | 4.11 |
|
| Abeona Therapeutics Com New (ABEO) | 0.1 | $1.8M | -60% | 400k | 4.48 |
|
| Fate Therapeutics (FATE) | 0.1 | $1.4M | 1.2M | 1.20 |
|
|
| Neumora Therapeutics (NMRA) | 0.0 | $858k | -54% | 440k | 1.95 |
|
| Lexicon Pharmaceuticals Com New (LXRX) | 0.0 | $624k | NEW | 400k | 1.56 |
|
| Rocket Pharmaceuticals (RCKT) | 0.0 | $358k | 100k | 3.58 |
|
Past Filings by Tang Capital Management
SEC 13F filings are viewable for Tang Capital Management going back to 2011
- Tang Capital Management 2026 Q1 filed May 15, 2026
- Tang Capital Management 2025 Q4 filed Feb. 17, 2026
- Tang Capital Management 2025 Q3 filed Nov. 14, 2025
- Tang Capital Management 2025 Q2 filed Aug. 14, 2025
- Tang Capital Management 2025 Q1 filed May 15, 2025
- Tang Capital Management 2024 Q4 filed Feb. 14, 2025
- Tang Capital Management 2024 Q3 filed Nov. 14, 2024
- Tang Capital Management 2024 Q2 filed Aug. 14, 2024
- Tang Capital Management 2024 Q1 filed May 15, 2024
- Tang Capital Management 2023 Q4 filed Feb. 14, 2024
- Tang Capital Management 2023 Q3 filed Nov. 14, 2023
- Tang Capital Management 2023 Q2 filed Aug. 14, 2023
- Tang Capital Management 2023 Q1 filed May 15, 2023
- Tang Capital Management 2022 Q4 filed Feb. 14, 2023
- Tang Capital Management 2022 Q3 filed Nov. 14, 2022
- Tang Capital Management 2022 Q2 filed Aug. 15, 2022